Treating atopic dermatitis at the source: Corrective barrier repair therapy based upon new pathogenic insights

Expert Review of Dermatology

Volumn 8, Issue 1, 2013, Pages 27-36

  Elias, Peter M ^a   Sun, Richard ^a   Eder, Angela R ^a   Wakefield, Joan S ^a   Man, Mao Qiang ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

antimicrobial peptides; atopic dermatitis; barrier function; barrier repair; filaggrin; LEKTI; Netherton syndrome; PAR2; pH; Staphylococcus aureus

Indexed keywords

ANTIHISTAMINIC AGENT; BETA DEFENSIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; FILAGGRIN; FLUTICASONE PROPIONATE; GLUCOCORTICOID; IMMUNOGLOBULIN E; KALLIKREIN; PETROLATUM;

ATOPIC DERMATITIS; BACTERIAL COLONIZATION; DISEASE EXACERBATION; GENETIC DISORDER; HUMAN; ICHTHYOSIS PREMATURITY SYNDROME; ICHTHYOSIS VULGARIS; MENTAL STRESS; MOLECULAR GENETICS; NETHERTON DISEASE; NEUTRAL LIPID STORAGE DISEASE; NONHUMAN; PRIORITY JOURNAL; PRURITUS; REVIEW; SECONDARY INFECTION; SKIN PERMEABILITY; STAPHYLOCOCCUS AUREUS; STRATUM CORNEUM; TH2 CELL;

EID: 84873469301     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/edm.12.73     Document Type: Review

References (104)

1. Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv. Lipid Res. 24, 1-26 (1991
2. Caubet C, Jonca N, Brattsand M et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/ KLK7/hK7. J. Invest. Dermatol. 122(5), 1235-1244 (2004
3. Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T. A proteolytic cascade of kallikreins in the stratum corneum. J. Invest. Dermatol. 124(1), 198-203 (2005
4. Lin TK, Crumrine D, Ackerman LD et a.l. Cellular changes that accompany shedding of human corneocytes. J. Invest. Dermatol. 32(10), 2430-2439 (2012
5. Braff MH, Di Nardo A, Gallo RL. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J. Invest. Dermatol. 124(2), 394-400 (2005
6. Oren A, Ganz T, Liu L, Meerloo T. In human epidermis, β-defensin 2 is packaged in lamellar bodies. Exp. Mol. Pathol. 74(2), 180-182 (2003
7. Aberg KM, Radek KA, Choi EH et al. Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J. Clin. Invest. 117(11), 3339-3349 (2007
8. Elias PM. Stratum corneum defensive functions: An integrated view. J. Invest. Dermatol. 125(2), 183-200 (2005
9. Elias PM, Choi EH. Interactions among stratum corneum defensive functions. Exp. Dermatol. 14(10), 719-726 (2005
10. Elias PM. The skin barrier as an innate immune element. Semin. Immunopathol(1), 3-14 (2007
11. Cork MJ, Danby SG, Vasilopoulos Y et al. Epidermal barrier dysfunction in atopic dermatitis. J. Invest. Dermatol. 129(8), 1892-1908 (2009
12. Sugarman JL, Fluhr JW, Fowler AJ, Bruckner T, Diepgen TL, Williams M.L. The objective severity assessment of atopic dermatitis score: An objective measure using permeability barrier function and tratum corneum hydration with computer-assisted estimates for extent of disease. Arch. Dermatol. 139(11), 1417-1422 (2003
13. Seidenari S, Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: A study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm. Venereol (6), 429-433 (1995
14. Eberlein-König B, Schäfer T, Huss-Marp J et al. Skin surface pH, stratum corneum hydration, trans-epidermal water loss and skin roughness related to atopic eczema and skin dryness in a population of primary school children. Acta Derm. Venereol(3), 188-191 (2000
15. Chamlin SL, Kao J, Frieden IJ et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity. J. Am. Acad. Dermatol. 47(2), 198-208 (2002
16. Denda M, Sato J, Tsuchiya T, Elias PM, Feingold KR. Low humidity stimulates epidermal DNA synthesis and amplifies the hyperproliferative response to barrier disruption: Implication for seasonal exacerbations of inflammatory dermatoses. J. Invest. Dermatol. 111(5), 873-878 (1998
17. Proksch E, Fölster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. J. Dermatol. Sci. 43(3), 159-169 (2006
18. Boguniewicz M, Leung DY. 10. Atopic dermatitis. J. Allergy Clin. Immunol(2 Suppl. Mini-Primer), S475-S480
19. Baker BS. The role of microorganisms in atopic dermatitis. Clin. Exp. Immunol (1), 1-9 (2006
20. Elias PM, Wood LC, Feingold K.R. Relationship of the epidermal permeability barrier to irritant contact dermatitis. Immunol. Allergy Clin. North America 17, 417-430 (1997
21. Elias PM, Wood LC, Feingold KR. Epidermal pathogenesis of inflammatory dermatoses. Am. J. Contact Dermatitis 10(3), 119-126 (1999
22. Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch. Dermatol. 137(8), 1079-1081 (2001
23. Taïeb A. Hypothesis: From epidermal barrier dysfunction to atopic disorders. Contact Derm. 41(4), 177-180 (1999
24. Cork MJ, Britton J, Butler L, Young S, Murphy R, Keohane SG. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br. J. Dermatol. 149(3), 582-589 (2003
25. Draelos ZD. New treatments for restoring impaired epidermal barrier permeability: Skin barrier repair creams. Clin. Dermatol (3), 345-348 (2012
26. Aly R, Maibach HI, Shinefield HR. Microbial flora of atopic dermatitis. Arch. Dermatol. 113(6), 780-782 (1977
27. Boguniewicz M, Schmid-Grendelmeier P, Leung DY. Atopic dermatitis. J. Allergy Clin. Immunol. 118(1), 40-43 (2006
28. Ramirez de Knott HM, McCormick TS, Kalka K et al. Cutaneous hypersensitivity to Malassezia sympodialis and dust mite in adult atopic dermatitis with a textile pattern. Contact Dermatitis 54, 92-99
29. Leung DY, Bieber T. Atopic dermatitis Lancet 361(9352), 151-160 (2003)
30. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347(15), 1151-1160 (2002
31. Aberg KM, Man MQ, Gallo RL et al. Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J. Invest. Dermatol (4), 917-925 (2008
32. Miller SJ, Aly R, Shinefeld HR, Elias PM. In vitro and in vivo antistaphylococcal activity of human stratum corneum lipids. Arch. Dermatol. 124(2), 209-215 (1988
33. Fluhr JW, Elias PM. Stratum corneum pH: Formation and function of the 'acid mantle'. Exog. Dermatol. 1, 163-175 (2002
34. Bibel DJ, Aly R, Shinefield HR. Antimicrobial activity of sphingosines. J. Invest. Dermatol. 98(3), 269-273 (1992
35. Thormar H, Hilmarsson H. The role of microbicidal lipids in host defense against pathogens and their potential as therapeutic agents. Chem. Phys. Lipids 150(1), 1-11 (2007
36. Clarke SR, Mohamed R, Bian L et al. The Staphylococcus aureus surface protein IsdA mediates resistance to innate defenses of human skin. Cell Host Microbe 1(3), 199-212 (2007
37. Nomura I, Goleva E, Howell MD et a.l. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J. mmunol. 171(6), 3262-3269
38. Zaiou M, Nizet V, Gallo RL. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37 prosequence. J. Invest. Dermatol. 120(5), 810-816 (2003
39. Komatsuzawa H, Ouhara K, Yamada S et al. Innate defences against methicillinresistant Staphylococcus aureus (MRSA infection. J. Pathol. 208(2), 249-260 (2006
40. Kisich KO, Howell MD, Boguniewicz M, Heizer HR, Watson NU, Leung DY. The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on β-defensin 3. J. Invest. Dermatol. 127(10), 2368-2380 (2007
41. Lomholt H, Andersen KE, Kilian M. Staphylococcus aureus clonal dynamics and virulence factors in children with atopic dermatitis. J. Invest. Dermatol. 125(5), 977-982 (2005
42. Wehner J, Neuber K. Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema. Br. J. Dermatol. 145(2), 302-305 (2001
43. Lehmann HS, Heaton T, Mallon D, Holt PG. Staphylococcal enterotoxin-B-mediated stimulation of interleukin-13 production as a potential aetiologic factor in eczema in infants. Int. Arch. Allergy Immunol. 135(4), 306-312 (2004
44. Langer K, Breuer K, Kapp A, Werfel T. Staphylococcus aureus-derived enterotoxins enhance house dust mite-induced patch test reactions in atopic dermatitis. Exp. Dermatol. 16(2), 124-129 (2007
45. Leung DY, Harbeck R, Bina P et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J. Clin. Invest. 92(3), 1374-1380 (1993
46. Gould HJ, Takhar P, Harries HE, Chevretton E, Sutton BJ. The allergic march from Staphylococcus aureus superantigens to immunoglobulin E. Chem. Immunol. Allergy 93, 106-136
47. ). 47 Sonkoly E, Muller A, Lauerma AI et al. IL-31: A new link between T cells and pruritus in atopic skin inflammation. J. Allergy Clin. Immunol. 117(2), 411-417 (2006
48. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 365(14), 1315-1327 (2011
49. Sandilands A, Smith FJ, Irvine AD, McLean WH. Filaggrin's fuller figure: A glimpse into the genetic architecture of atopic dermatitis. J. Invest. Dermatol(6), 1282-1284 (2007
50. Weidinger S, Rodríguez E, Stahl C et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis J. Invest. Dermatol. 127(3), 724-726 (2007
51. Gruber R, Elias PM, Crumrine D et al. Filaggrin genotype in ichthyosis vulgaris predicts abnormalities in epidermal structure and function. Am. J. Pathol (5), 2252-2263 (2011
52. Presland R, Rothnagal J, Lawrence O. Profilaggrin and the fused S100 family of calcium-binding proteins. In: Skin Barrier. Elias P, Feingold K (Eds). Taylor & Francis, NY, USA, 111-140 (2006
53. Yoneda K, Nakagawa T, Lawrence OT et al. Interaction of the profilaggrin N-terminal domain with loricrin in human cultured keratinocytes and epidermis. J. Invest. Dermatol. 132(4), 1206-1214 (2012
54. Hoste E, Kemperman P, Devos M et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J. Invest. Dermatol. 131(11), 2233-2241 (2011
55. Scott IR, Harding CR. Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the water activity of the environment. Dev. Biol. 115(1), 84-92
56. ). 56 Krien PM, Kermici M. Evidence for the existence of a self-regulated enzymatic process within the human stratum corneum -an unexpected role for urocanic acid. J. Invest. Dermatol. 115(3), 414-420 (2000
57. Kelsell DP, Byrne C. SNPing at the epidermal barrier. J. Invest. Dermatol (8), 1593-1595 (2011
58. Marenholz I, Rivera VA, Esparza-Gordillo J et al. Association screening in the epidermal differentiation complex (EDC identifies an SPRR3 repeat number variant as a risk factor for eczema. J. Invest Dermatol. 131(8), 1644-1649 (2011)
59. Walley AJ, Chavanas S, Moffatt MF et al. Gene polymorphism in Netherton and common atopic disease. Nat. Genet. 29(2), 175-178 (2001
60. Fortugno P, Bresciani A, Paolini C et al. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: Implications for skin homeostasis. J. Invest. Dermatol (11), 2223-2232 (2011
61. Hachem JP, Wagberg F, Schmuth M et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J. Invest. Dermatol (7), 1609-1621 (2006
62. Hachem JP, Crumrine D, Fluhr J, Brown BE, Feingold KR, Elias PM. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. J. Invest. Dermatol (2), 345-353 (2003
63. Komatsu N, Takata M, Otsuki N et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J. Invest. Dermatol. 118(3), 436-443 (2002
64. Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm. Venereol (1), 27-30 (1998
65. Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: An etiologic factor in atopic dry skiñJ. Invest. Dermatol. 96(4), 523-526
66. Hatano Y, Man MQ, Uchida Y et al. Maintenance of an acidic stratum corneum prevents emergence of murine atopic dermatitis. J. Invest. Dermatol. 129(7), 1824-1835 (2009
67. Hachem JP, Houben E, Crumrine D et al. Serine protease signaling of epidermal permeability barrier homeostasis. J. Invest. Dermatol. 126(9), 2074-2086 (2006
68. Demerjian M, Hachem JP, Tschachler E et al. Acute modulations in permeability barrier function regulate epidermal cornification: Role of caspase-14 and the protease-activated receptor type 2. Am. J. Pathol. 172(1), 86-97 (2008
69. Sator PG, Schmidt JB, Hönigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J. Am. Acad. Dermatol. 48(3), 352-358 (2003
70. Janssens M, van Smeden J, Gooris GS et al. Lamellar lipid organization and ceramide composition in the stratum corneum of patients with atopic eczema. J. Invest. Dermatol. 131(10), 2136-2138 (2011
71. Cork MJ, Robinson DA, Vasilopoulos Y et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. J. Allergy Clin. Immunol. 118(1), 3-21; quiz 22 (2006
72. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J. Allergy Clin. Immunol. 121(6), 1337-1343 (2008
73. Elias PM, Wakefield JS. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. Clin. Rev. Allergy Immunol. 41(3), 282-295 (2011
74. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr. Opin. Allergy Clin Immunol. 9(5), 437-446 (2009
75. Garg A, Chren MM, Sands LP et al. Psychological stress perturbs epidermal permeability barrier homeostasis: Implications for the pathogenesis of stress-associated skin disorders. Arch. Dermatol. 137(1), 53-59 (2001
76. Altemus M, Rao B, Dhabhar FS, Ding W, Granstein RD. Stress-induced changes in skin barrier function in healthy women. J. Invest. Dermatol. 117(2), 309-317
77. ). 77 Denda M, Tsuchiya T, Elias PM, Feingold KR. Stress alters cutaneous permeability barrier homeostasis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278(2), R367-R372 (2000
78. Choi EH, Demerjian M, Crumrine D et al. Glucocorticoid blockade reverses psychological stress-induced abnormalities in epidermal structure and function. Am. J. Physiol. Regul. Integr. Comp. Physiol (6), R1657-R1662 (2006
79. Choi EH, Brown BE, Crumrine D et al. Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J. Invest. Dermatol. 124(3), 587-595 (2005
80. Hachem JP, Fowler A, Behne M et al. Increased stratum corneum pH promotes activation and release of primary cytokines from the stratum corneum attributable to activation of serine proteases. J. Invest. Dermatol. 119, 258 (2002
81. Nylander-Lundqvist E, Bäck O, Egelrud T. IL-1 β activation in human epidermis. J. Immunol. 157(4), 1699-1704 (1996
82. Hudson TJ. Skin barrier function and allergic risk. Nat. Genet. 38(4), 399-400 (2006
83. Briot A, Deraison C, Lacroix M et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in etherton syndrome. J. Exp. Med. 206(5), 1135-1147 (2009
84. Kurahashi R, Hatano Y, Katagiri K. IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo. J. Invest. Dermatol. 128(5), 1329-1331 (2008
85. Hatano Y, Terashi H, Arakawa S, Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-α and interferon-γ in human epidermis. J. Invest. Dermatol (4), 786-792 (2005
86. Howell MD, Kim BE, Gao P et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J. Allergy Clin. Immunol. 120(1), 150-155 (2007
87. Hatano Y, Adachi Y, Elias PM et al. The Th2 cytokine, interleukin-4, abrogates the cohesion of normal stratum corneum in mice: Implications for pathogenesis of atopic dermatitis. 22(1), 30-35 (2012
88. Kobayashi J, Inai T, Morita K et al. Reciprocal regulation of permeability through a cultured keratinocyte sheet by IFN-γ and IL-4. Cytokine 28(4-5), 186-189 (2004
89. Lin TK, Man MQ, Santiago JL et al. Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function. J. Invest. Dermatol. 133(2), 469-478 (2012
90. Grether-Beck S, Felsner I, Brenden H et al. Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression. J. Invest. Dermatol. 132(6), 1561-1572
91. Ghadially R, Halkier-Sorensen L, Elias PM. Effects of petrolatum on stratum corneum structure and function. J. Am. Acad. Dermatol. 26(3 Pt 2), 387-396 (1992
92. Brown B, Diembeck W, Hoppe U, Elias P. Fate of topical hydrocarbons in the skin. J. Soc. Cosm. Chem. 46, 1-9 (1995
93. Simpson E, Berry T, Tofte S, Hanifin JM, Eichenfield L. EpiCeram for the treatment of mild-to-moderate atopic dermatitis - a pilot study. IID 2008 Kyoto, Japan (2008
94. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J. Drugs Dermatol. 8(12), 1106-1111 (2009
95. Man MQ, Feingold KR, Elias PM. Exogenous lipids influence permeability barrier recovery in acetone-treated murine skin. Arch. Dermatol. 129(6), 728-738 (1993
96. Mao-Qiang M, Brown BE, Wu-Pong S, Feingold KR, Elias PM. Exogenous nonphysiologic vs physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch. Dermatol. 131(7), 809-816 (1995
97. Man MQ M, Feingold KR, Thornfeldt CR, Elias PM Optimization of physiological lipid mixtures for barrier repair J. Invest. Dermatol. 106(5), 1096-1101 (1996
98. Bikowski J. Case studies assessing a new skin barrier repair cream for the treatment of atopic dermatitis. J. Drugs Dermatol (11), 1037-1041 (2009
99. Man MQ, Sun R. Comparative efficacy of various 'barrier repair' ingredients and formulations on barrier homeostasis, inflammation, and antimicrobial peptide expression. Presented at: IID 2013 Edinburgh, Scotland, 8-13 May 2013
100. Zettersten EM, Ghadially R, Feingold KR, Crumrine D, Elias PM. Optimal ratios of topical stratum corneum lipids improve barrier recovery in chronologically aged skin. J. Am. Acad. Dermatol. 37(3 Pt 1), 403-408 (1997
101. Ghadially R, Brown BE, Sequeira-Martin SM, Feingold KR, Elias PM. The aged epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. J. Clin. Invest. 95(5), 2281-2290 (1995
102. Yang L, Mao-Qiang M, Taljebini M, Elias PM, Feingold KR. Topical stratum corneum lipids accelerate barrier repair after tape stripping, solvent treatment and some but not all types of detergent treatment. Br. J. Dermatol. 133(5), 679-685 (1995
103. Hong SP, Kim MJ, Jung MY et al. Biopositive effects of low-dose UVB on epidermis: Coordinate upregulation of antimicrobial peptides and permeability barrier reinforcement. J. Invest. Dermatol (12), 2880-2887 (2008
104. Elias PM. Barrier-repair therapy for atopic dermatitis: Corrective lipid biochemical therapy. Exp. Rev. Dermatol. 3, 441-452